Fengyi Mao

Fengyi Mao

Auto-generated profile, based on publicly available information

Fengyi Mao

Department of Toxicology and Cancer Biology University of Kentucky Lexington Kentucky USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2023 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
CLChaohao Li
Chaohao Li
DADerek B Allison
Derek B Allison
DHDaheng He
Daheng He
FMFengyi Mao
Fengyi Mao
XWXinyi Wang
Xinyi Wang
XLXiaoqi Liu
Xiaoqi Liu
Metastasis of lung adenocarcinoma (LUAD) is a major cause of death in patients. Aryl hydrocarbon receptor (AHR), an important transcription factor, is involved in the initiation and progression of lung cancer. Polo-like kinase 1 (PLK1), a serine/threonine kinase, acts as an oncogene promoting the malignancy of multiple cancer types. However, the interaction between these two factors and their significance in lung cancer remain to be determined. In this study, we demonstrate that PLK1 phosphorylates AHR at S489 in LUAD, leading to epithelial-mesenchymal transition (EMT) and metastatic events. RNA-seq analyses reveal that type 2 deiodinase (DIO2) is responsible for EMT and enhanced metastatic potential. DIO2 converts tetraiodothyronine (T4) to triiodothyronine (T3), activating thyroid hormone (TH) signaling. In vitro and in vivo experiments demonstrate that treatment with T3 or T4 promotes the metastasis of LUAD, whereas depletion of DIO2 or a deiodinase inhibitor disrupts this property. Taking together, our results identify the AHR phosphorylation by PLK1 and subsequent activation of DIO2-TH signaling as mechanisms leading to LUAD metastasis. These findings can inform possible therapeutic interventions for this event.

24 November 2025 in PLOS Biology
Verified
Journal Article
Open access
FMFengyi Mao
Fengyi Mao
SWSai Wu
Sai Wu
DADerek B. Allison
Derek B. Allison
DHDaheng He
Daheng He
YKYifan Kong
Yifan Kong
XLXiaoqi Liu
Xiaoqi Liu
Polo-like kinase 1 (PLK1), a critical cell cycle regulator, is associated with cancer progression and negatively correlates with patient survival in cutaneous melanoma based on clinical database analysis. In a melanoma mouse model induced by BRaf CA mutation and Pten -deficiency, we observed that PLK1 overexpression mediated metabolic reprogramming to markedly accelerate tumor growth, promote metastasis, and shortened mice survival. Mechanistically, PLK1 stabilizes BTB domain and CNC homolog 1 (BACH1), which serves as a crucial transcription factor for genes involved in cancer metabolism and metastasis. Moreover, the PLK1/BACH1 axis confers resistance to Vemurafenib, a BRAF V600E inhibitor, in melanoma. In light of this finding, we attempted an innovative pharmacological combination targeting both BRAF V600E and PLK1, identifying a synergistic efficiency to this approach to suppress tumor growth. Overall, we have discovered a novel function of PLK1 that is independent of the cell cycle, which could pave new ways for melanoma therapies.

24 March 2022 in The Prostate
Verified
Journal Article
Closed access
FMFengyi Mao
Fengyi Mao
YKYifan Kong
Yifan Kong
JLJinghui Liu
Jinghui Liu
XRXiongjian Rao
Xiongjian Rao
CLChaohao Li
Chaohao Li
XLXiaoqi Liu
Xiaoqi Liu